Healthcare Business

4 Biotech Stocks Could Have Big Upside Before Russell Index Changes

Opko Health

This company is a multinational biopharmaceutical and diagnostics participant. Opko Health Inc. (NYSE: OPK) seeks to establish industry leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies. Shareholders will be glad to know that the chairman of the board has consistently been a buyer of the stock.

The company announced last week the acquisition of EirGen Pharma, a growing, profitable and cash flow positive specialty pharmaceutical company focused on the development and commercial supply of high potency, high barrier to entry, pharmaceutical products for sale in the United States, Canada, Japan, Australia, most European countries, and more than 40 others around the world.

The company reported less than stellar earnings this week, and investors may have a good chance to buy shares at a discounted price. The consensus price target is $14.88, and shares closed on Monday at $14.30.

Puma Biotechnology

This stock has had a huge run over the past year. Puma Biotechnology Inc. (NASDAQ: PBYI) is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use.

The company is initially focused on the development of PB272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2-positive breast cancer and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation. A cocktail of drugs containing Puma’s neratinib given before surgery eliminated evidence of cancer in the breast and lymph nodes in 55.6% of women, compared with 32.6% of those given standard drug therapy in data released last year.

The consensus price target is a whopping $276.80. The stock closed Monday at $200.98 per share.

ALSO READ: RBC Raises Price Targets on 3 Top Mobile and Cloud Tech Stocks

It is important to remember that these are all very aggressive stocks and only suitable for high risk-tolerant accounts. With that in mind, if history is any guide, investors that buy these stocks now and sell before the actual Russell changes may be well rewarded.

Sponsored: Tips for Investing

A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.

Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.